Regulus Therapeutics Inc Forecasted to Earn Q1 2019 Earnings of ($0.69) Per Share (RGLS)

Regulus Therapeutics Inc (NASDAQ:RGLS) – Wedbush issued their Q1 2019 EPS estimates for Regulus Therapeutics in a report released on Tuesday, March 26th, Zacks Investment Research reports. Wedbush analyst L. Moussatos forecasts that the biopharmaceutical company will post earnings of ($0.69) per share for the quarter. Wedbush currently has a “Hold” rating and a $2.00 target price on the stock. Wedbush also issued estimates for Regulus Therapeutics’ Q2 2019 earnings at ($0.37) EPS, Q3 2019 earnings at ($0.53) EPS, Q4 2019 earnings at ($0.49) EPS, FY2019 earnings at ($2.09) EPS, Q1 2020 earnings at ($0.50) EPS, Q2 2020 earnings at ($0.52) EPS, Q3 2020 earnings at ($0.53) EPS, Q4 2020 earnings at ($0.55) EPS, FY2020 earnings at ($2.11) EPS, FY2021 earnings at ($2.38) EPS and FY2022 earnings at ($2.70) EPS.

A number of other analysts have also commented on RGLS. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research note on Friday, March 29th. Wells Fargo & Co reduced their price target on shares of Regulus Therapeutics from $6.00 to $1.50 and set a “market perform” rating for the company in a research note on Tuesday, March 19th. Six analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Regulus Therapeutics has an average rating of “Hold” and a consensus target price of $1.31.

Shares of RGLS stock traded up $0.09 during trading hours on Thursday, reaching $1.16. The company had a trading volume of 42,706 shares, compared to its average volume of 168,766. Regulus Therapeutics has a one year low of $0.80 and a one year high of $9.48.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.06). Regulus Therapeutics had a negative return on equity of 671.46% and a negative net margin of 67,650.01%. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $7.01 million.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Wedbush Securities Inc. boosted its holdings in shares of Regulus Therapeutics by 32.8% in the first quarter. Wedbush Securities Inc. now owns 43,489 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 10,751 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Regulus Therapeutics in the first quarter worth approximately $68,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Regulus Therapeutics by 396.3% in the third quarter. Renaissance Technologies LLC now owns 595,501 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 475,512 shares during the last quarter. 24.44% of the stock is currently owned by institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Further Reading: Inflation

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.